Mel Sorensen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesMel sorensenWilliam windhamTimothy bibaChristopher degnanExchange commissionSolebury strategic communicationsNicolaus company incGalera therapeutics incGalera therapeuticsRights agreementFast trackBreakthrough therapyPrivate securities litigation reform actOrphan drugFast track designations

Galera Therapeutics (GRTX) says FDA reiterated need for additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM

Galera Therapeutics (GRTX) says FDA reiterated need for additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMel sorensenNicolaus company incDrug administrationCompany new drug applicationGalera therapeutics incGalera therapeuticsUnited states foodNew drug applicationQuarterly report

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

31.10.2023 - FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder . Seite 1

United statesMel sorensenGalera therapeutics incDrug administrationCompany new drug applicationUnited states foodNew drug applicationGalera therapeutics chartAlera therapeutics kursAlera therapeutics aktie

Galera Therapeutics (NASDAQ: GRTX) in Focus: Exploring Catalysts Ahead of FDA s Verdict

Galera Therapeutics (NASDAQ: GRTX) experienced a significant 34% intraday surge on October 18, 2023. This explosive trading has captured the attention of investors, prompting curiosity about the company's efforts to innovate radiotherapy in cancer treatment. Despite the lack of updates on social media, press releases, or SEC filings, this sudden rise has left many intrigued

United statesMel sorensenTazeen ahmadGalera therapeuticsRight nowResponse letterMicrocap daily

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 Galera Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that.

United statesTimothy bibaMel sorensenChristopher degnanWilliam windhamExchange commissionCompany new drug applicationSolebury strategic communicationsDrug administrationGalera therapeutics incComplete response letterNew drug applicationFast trackBreakthrough therapyOrphan drug designationPrivate securities litigation reform act